Anifrolumab Treatment for 24 Weeks in Patients With Primary Sjögren's Syndrome

NCT05383677 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Sjogren's Syndrome

Interventions

DRUG: Anifrolumab
DRUG: Placebo

Sponsor

University Medical Center Groningen

Collaborators

[object Object]